1309832-72-1

Upstream product

• 65295-69-4 2,6-difluorophenyl isocyanate 

Downstream Products

• 1309832-74-3 1-(2,6-difluoro-5-nitrophenyl)-4-methyl-5H-tetrazol-5-one 
• 1309832-75-4 1-(5-Amino-2,6-difluorophenyl)-4-methyl-5H-tetrazol-5-one 
• 1346564-56-4 C₂₄H₁₉F₂N₅O₅ 
• 1346565-85-2 C₂₀H₁₈F₂N₆O₄ 
• 1346563-44-7 C₁₉H₁₇F₂N₅O₅ 
• 1346567-70-1 C₃₅H₃₁F₂N₅O₆ 
• 1346564-59-7 C₃₁H₂₅F₂N₅O₅ 
• 1346567-61-0 C₂₇H₂₄F₂N₆O₄ 
• 1346563-48-1 C₂₆H₂₃F₂N₅O₅ 
• 1309832-73-2 1-(2,6-difluorophenyl)-4-methyl-5H-tetrazol-5-one 

Relevant academic research and scientific papers

NOVEL TETRAZOLONE DERIVATIVES

The invention relates to a compound of formula (I), wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

PROTEIN KINASE C INHIBITORS AND USES THEREOF

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE

Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.